Navigation Links
EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.
Date:8/19/2013

4C101, in effect at the start of trading on Wednesday, August 21, 2013.

"The milestones we have achieved today represent the penultimate step in our merger with Immune Pharmaceuticals Ltd.," stated Robert Cook, Interim President and CEO of EpiCept.  "We anticipate that we will formally complete the  merger by the end of the week, at which time we will become Immune Pharmaceuticals Inc."

The 1-for-40 reverse stock split will automatically convert every forty outstanding pre-split shares of the Company's common stock into one outstanding new post-split share of common stock of the re-named Company, Immune Pharmaceuticals Inc.  If the number of shares held by a particular stockholder is not evenly divisible by the ratio of the reverse split, the stockholder's new share count will be rounded up to the nearest whole share.  The reverse split and change of name were authorized by the Company's stockholders on August 6, 2013.  The reverse split will reduce the number of outstanding shares of common stock from 110,252,876 (excluding those shares owned by Immune Pharmaceuticals Ltd.) to 2,756,322, plus those additional shares issued as a result of rounding up.  Upon completion of the merger between the companies, the total outstanding shares of the re-named Company, Immune Pharmaceuticals Inc., will be approximately 12.6 million.

The number of shares of common stock subject to outstanding stock options, stock warrants or convertible securities, and the exercise prices and conversion ratios of those securities, will automatically be proportionately adjusted for the 1-for-40 ratio provided for by the reverse stock split.

In order to effectuate the reverse stock split and change of corporate name, a Certificate of Amendment to EpiCept's Third Amended and Restated Certificate of Incorporation was filed in Delaware on Thursday, August 15, 2013, and will become
'/>"/>

SOURCE EpiCept Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. EpiCept Reports Second Quarter 2013 Operating and Financial Results
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... The Pistoia Alliance, a global, not-for-profit alliance of ... to innovation in R&D, has announced the start of ... Mapping project has been set up to create better ... life sciences R&D. The project will see the Pistoia ... services to enable the universal application of ontologies. , ...
(Date:4/28/2015)... 28, 2015 According to a 2013 ... patients receive medical treatment from burn injuries per year. ... injury, extensive formation of scars with subsequent contractures remains ... for which there is no adequate treatment. Contractures are ... movement and can cause permanent deformity. , Synedgen ...
(Date:4/28/2015)... Reproductive endocrinologist Dr. Kaylen Silverberg , ... battling infertility in this country, testified on behalf of ... first state in the nation to consider creating a clearinghouse ... who desire to receive them. , Infertility affects over 7.3 ... is one of the few medical diseases that is curable, ...
(Date:4/27/2015)... HEIDELBERG , Alemania, April 27, 2015 ... un nuevo receptor utilizando tecnología de descubrimiento de biomarcador ... en el tratamiento de millones de pacientes con cáncer ... que ha recibido una patente en Europa titulada "Tissue ... de Molecular Health de que EPHB4 es un nuevo ...
Breaking Biology Technology:Pistoia Alliance Announces Start of Ontologies Mapping Project 2Synedgen Burn Treatment Results Presented at Premier Wound Conference 2Synedgen Burn Treatment Results Presented at Premier Wound Conference 3Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas 2Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas 3Molecular Health obtiene la patente para un nuevo receptor 2Molecular Health obtiene la patente para un nuevo receptor 3
... definitive agreement with Elan Pharmaceuticals, Inc. (a subsidiary of Elan Corporation, plc) ( ELN) ("Elan") to acquire the analgesic therapy, PRIALT(R) (ziconotide intrathecal infusion). , ... , ... ... ...
... March 11 /PRNewswire/ - Trillium Therapeutics Inc. (TTI), ... it has entered into two definitive license agreements with University ... in Toronto, Ontario , granting Trillium exclusive worldwide rights ... stem cell transplantation and cancer. , ...
... President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Roth 22nd Annual OC Growth Conference in Laguna Niguel . , ... , ... ... ...
Cached Biology Technology:Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 2Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 3Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 4Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 5Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 6Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs 2Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs 3Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference 2
(Date:4/20/2015)... April 20, 2015 Huntington Memorial Hospital is ... implant a new miniaturized, wireless monitoring sensor to manage ... first and only FDA-approved heart failure monitoring device that ... used by physicians to manage heart failure. ... implanted in the pulmonary artery (PA) during a non-surgical ...
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... for the 2015 New York Design Awards under the ... New York City Design Awards are part of a ... over 2,500 ratings from the marketplace, industry and judging ...
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2
... by two Queens scientists has resulted in an exciting new ... chemical weapons and pesticides. Recently completed testing by an ... be greater than 99 per cent effective when used on ... tested in solution, full destruction of all three agents was ...
... genetic modification (GM) and RNA Interference are being deployed ... series of European and global initiatives. The ground was ... that exploit these technologies at a recent workshop organised ... highlighted the interlocking themes underlying the debate over livestock ...
... in molecular targeting, translational cancer research and cancer ... 17,000 scientists from around the world gather at ... the 2008 Annual Meeting of the American Association ... the meeting will include late-breaking clinical trial findings ...
Cached Biology News:Queen's develops safe 'green' decontamination method 2Europe develops new technologies to boost health of livestock 2Europe develops new technologies to boost health of livestock 3AACR annual meeting showcases developments in understanding and targeting cancers 2AACR annual meeting showcases developments in understanding and targeting cancers 3
...
...
...
Sold individually or included in the MasterAmp™ PCR Optimization Kit without ammonium sulfate. Includes dNTPs, buffer, and varying amounts of MgCl2 and the MasterAmp™ PCR Enhancer (with be...
Biology Products: